Alternatives and Considerations for Clinical Scenario 1

Author(s):

The panel presents alternative treatment options and key considerations for the discussed clinical scenario, elaborating on the factors that influence their decision-making process.

EP: 1.Overview of pLGG presentation and categorization

EP: 2.Molecular Characterization of pLGG

EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations

EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors

EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors

EP: 6.Current Treatment of Patients with NF1 pLGG

EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG

EP: 8.Treatment Considerations for Progressive pLGG

EP: 9.Radiation and Targeted Therapies for Progressive pLGG

EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG

EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting

EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion

Now Viewing

EP: 13.Alternatives and Considerations for Clinical Scenario 1

EP: 14.Clinical Scenario 2 - BRAFV600E

EP: 15.Potential Adverse Events With Targeted Therapies

EP: 16.Clinical Insights: Looking Forward for pLGG

Of the possible options, what treatment approach would you select for this patient?
1. What key clinical or patient-specific factors informed this choice?